Multiple Myeloma is a cancer that begins in the bone marrow, the soft, spongy tissue found inside most bones. Specifically, it affects plasma cells a type of white blood cell crucial for the immune system. When these cells become cancerous, they accumulate in the bone marrow, crowding out healthy blood cells and producing abnormal proteins that can cause significant complications throughout the body.
For patients facing this diagnosis, the treatment landscape has evolved dramatically. While Multiple Myeloma was once considered difficult to manage, modern advancements, particularly in the field of stem cell transplantation, have significantly improved survival rates and quality of life. At Liv Hospital, our dedicated Hematology and Bone Marrow Transplant Unit utilizes these advanced cellular therapies to offer patients a robust defense against this complex disease.
Understanding the Enemy: What is Multiple Myeloma?
To understand the treatment, one must first understand the disease mechanism. Healthy plasma cells help you fight infection by making antibodies that recognize and attack germs. In Multiple Myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than producing helpful antibodies, the cancer cells produce abnormal proteins (monoclonal proteins or M proteins) that can cause complications.
The proliferation of these cells leads to a specific set of symptoms, often remembered by the acronym CRAB:
- C – Calcium Elevation: The breakdown of bone releases calcium into the blood (hypercalcemia), causing thirst, nausea, and confusion.
- R – Renal (Kidney) Failure: The excess M proteins can damage the kidneys’ filtration system.
- A – Anemia: As cancer cells crowd the marrow, red blood cell production drops, leading to fatigue and weakness.
- B – Bone Abnormalities: Myeloma cells trigger the breakdown of old bone without replacing it with new bone, leading to pain, fractures (lytic lesions), and osteoporosis.
The Role of Stem Cell Transplantation
For many years, the standard of care for eligible patients has been High-Dose Chemotherapy followed by an Autologous Stem Cell Transplant (ASCT).
It is important to clarify a common misconception: the stem cells themselves do not fight the cancer in this scenario. Instead, the transplant is a “rescue” procedure. The most effective drug for killing myeloma cells is a chemotherapy agent called melphalan. However, the dose required to effectively wipe out the cancer is so high that it would permanently destroy the patient’s bone marrow.
By collecting the patient’s healthy stem cells before the high-dose chemotherapy and re-infusing them after, doctors can safely administer the potent treatment needed to achieve deep remission. This process allows the bone marrow to regenerate and resume normal blood production.
For detailed information on eligibility and our specific protocols, we invite you to explore our resource page on Stem Cell Multiple Myeloma.
The Transplant Process: A Step-by-Step Journey
Undergoing a stem cell transplant is a significant commitment that involves several distinct phases.
1. Induction Therapy
Before a transplant can even be considered, the active cancer must be brought under control. Patients typically undergo 3 to 4 cycles of drug therapy (often a combination of targeted drugs and steroids) to reduce the number of myeloma cells in the body. The goal is to enter the transplant phase with the lowest possible disease burden.
2. Stem Cell Mobilization and Collection
Once the disease is stabilized, the patient receives growth factor injections (G-CSF) to stimulate the bone marrow to release stem cells into the bloodstream. These cells are then collected through a process called apheresis. Blood is drawn from one arm, passed through a machine that separates out the stem cells, and returned to the other arm. These cells are then frozen and stored cryogenically.
3. Conditioning (High-Dose Therapy)
This is the therapeutic core of the process. The patient receives high doses of chemotherapy (melphalan) to kill the remaining myeloma cells in the bone marrow. This treatment is potent and typically requires a hospital stay to monitor for side effects.
4. The Transplant (Infusion)
A day or two after chemotherapy, the stored stem cells are thawed and infused back into the patient’s bloodstream through a central line. This process is painless and resembles a blood transfusion. The stem cells “home” to the bone marrow and begin the work of rebuilding the immune system.
5. Engraftment and Recovery
The weeks following the transplant are critical. The patient’s blood counts will drop significantly, leaving them vulnerable to infection. During this time, supportive care including antibiotics and blood transfusions is provided until “engraftment” occurs, which is when the new stem cells start producing healthy blood cells.
Autologous vs. Allogeneic: Which is Used?
In the vast majority of Multiple Myeloma cases, an Autologous Transplant (using the patient’s own cells) is performed. It has a low mortality rate and is highly effective at extending remission.
An Allogeneic Transplant (using donor cells) is much rarer for myeloma. While it offers the potential benefit of the “graft-versus-myeloma” effect (where donor cells attack the cancer), it carries a significantly higher risk of complications, such as Graft-Versus-Host Disease (GVHD). It is typically reserved for younger patients with high-risk disease or those who have relapsed after other treatments.
The Road Ahead: Maintenance and Monitoring
It is important to understand that while a stem cell transplant can induce a long period of remission, Multiple Myeloma is currently considered a treatable but generally incurable condition. Therefore, after the transplant recovery is complete, most patients are placed on “maintenance therapy” a low-dose drug regimen designed to keep the cancer suppressed for as long as possible.
Advances in immunotherapy, such as CAR-T cell therapy and bispecific antibodies, are also emerging as powerful options for patients who relapse, offering new hope when standard treatments stop working.
Embracing a Holistic Recovery
Living with Multiple Myeloma and recovering from a transplant requires resilience. It is not just about medical treatments; it is about rebuilding your body and mind. Bone health, kidney protection, and immune system support become daily priorities. We encourage patients to adopt a comprehensive approach to their well-being, focusing on nutrient-dense nutrition to combat anemia, gentle exercise to strengthen bones without risking fracture, and stress-reduction techniques to aid immune recovery. For expert advice on integrating these healthy habits into your daily life, please visit live and feel to support your journey toward vitality and balance.
